Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
An Evaluation of the Bioequivalence of Five 0.1 mg GI198745/Dutasteride Soft Gelatin Capsules Compared to One 0.5 mg GI198745/Dutasteride Gelatin Capsules in Healthy Male Volunteers
In the register
The register attaches this trial to Dutasteride (Avodart / Zagallo) (GSK), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1
- Sponsor
- GlaxoSmithKline
- Participants (registry)
- 36
- Start
- September 2013
- Primary completion
- January 2014
- Study completion
- January 2014
- Last registry update
- June 2018
- Countries
- Australia
Conditions studied: Alopecia
Interventions: GI198745 0.1 mg, GI198745 0.5 mg
Other trials of Dutasteride (Avodart / Zagallo)
Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
- NCT01004809Completed
AVODART® Alopecia Post-marketing Surveillance (PMS)
A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.